TIZIMLI QIZIL YUGURIK KASALLIGIDA BIOKIMYOVIY O‘ZGARISHLAR VA ULARNING KLINIK-DIAGNOSTIK AHAMIYATI

Authors

  • Kuranova Sevaraxon Saidolimovna Andijon davlat tibbiyot instituti Biologik kimyo kafedrasi katta o‘qituvchisi Author
  • Karimjonova Odina Qosimjon qizi Andijon davlat tibbiyot instituti talabasi Author
  • Turg’unpo‘latova Mahliyo Odiljon qizi Andijon davlat tibbiyot instituti talabasi Author

Keywords:

tizimli qizil yugurik, biokimyoviy markerlar, oksidlovchi stress, komplement tizimi, anti-dsDNA, C-reaktiv oqsil, lupus nefriti, kreatinin, albumin, lipid almashinuvi.

Abstract

izimli qizil yugurik (TQY) — immun tizimining disregulyatsiyasi, autoantitanalar hosil bo‘lishi, immun komplekslarning to‘planishi va ko‘p a’zoli zararlanish bilan kechuvchi surunkali autoimmun kasallikdir. Kasallik patogenezida immunologik jarayonlar bilan bir qatorda oksidlovchi stress, mitoxondrial disfunksiya, komplement tizimi faolligining o‘zgarishi, oqsil va lipidlar almashinuvining buzilishi hamda buyrak faoliyatidagi o‘zgarishlar muhim ahamiyatga ega. Mazkur maqolaning maqsadi tizimli qizil yugurikda kuzatiladigan asosiy biokimyoviy o‘zgarishlarni tahlil qilish va ularning klinik-diagnostik ahamiyatini yoritishdan iborat.

References

1.Tsokos G.C. Systemic lupus erythematosus. New England Journal of Medicine. 2011;365:2110–2121. DOI: https://doi.org/10.1056/NEJMra1100359

2.Kaul A., Gordon C., Crow M.K., et al. Systemic lupus erythematosus. Nature Reviews Disease Primers. 2016;2:16039. DOI: https://doi.org/10.1038/nrdp.2016.39

3.Fanouriakis A., Kostopoulou M., Alunno A., et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2019;78(6):736–745. DOI: https://doi.org/10.1136/annrheumdis-2019-215089

4.Mosca M., Tani C., Aringer M., et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Annals of the Rheumatic Diseases. 2010;69(7):1269–1274. DOI: https://doi.org/10.1136/ard.2009.117200

5.Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney International. 2024;105(1S)–S69. Qo‘llanma: https://kdigo.org/guidelines/lupus-nephritis/

6.Fanouriakis A., Kostopoulou M., Andersen J., et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Annals of the Rheumatic Diseases. 2026;85(1):75–90. DOI: https://doi.org/10.1016/j.ard.2025.09.007

7.Bertsias G.K., Tektonidou M., Amoura Z., et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases. 2012;71(11):1771–1782. DOI: https://doi.org/10.1136/annrheumdis-2012-201940

Downloads

Published

2026-10-16